Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](/images/logo/astrazeneca.png)
Roche's first FDA-approved tumour-agnostic medicine
- Details
- Category: Roche
![Roche Roche](/images/logo/roche.png)
Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](/images/logo/astrazeneca.png)
Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies
- Details
- Category: Boehringer Ingelheim
![Boehringer Ingelheim Boehringer Ingelheim](/images/logo/boehringer-ingelheim.png)
Lilly, Evidation Health and Apple study shows personal digital devices may help in the identification of mild cognitive impairment and mild Alzheimer's disease dementia
- Details
- Category: Eli Lilly and Company
![Eli Lilly and Company Eli Lilly and Company](/images/logo/lilly.png)
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
GSK completes transaction with Pfizer to form new world-leading Consumer Healthcare Joint Venture
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline GlaxoSmithKline](/images/logo/gsk.png)
More Pharma News ...
- Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
- Mylan and Upjohn, a division of Pfizer, to combine, creating a new champion for global health uniquely positioned to fulfill the world's need for medicine
- Amgen and Allergan's MVASI™ (bevacizumab-awwb) and KANJINTI™ (trastuzumab-anns) now available in the United States
- Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement
- FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
- Boehringer Ingelheim acquires AMAL Therapeutics, significantly enriching its cancer immunology portfolio with novel cancer vaccines platform
- Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention